The effectiveness and tolerability of tapentadol extended release ( ER ) , a centrally acting analgesic with - opioid receptor agonist and norepinephrine ( noradrenaline ) reuptake inhibitor activities , have been demonstrated in patients with chronic pain , including those switching directly from prior opioid therapy .